Original articleLiver injury during antituberculosis treatment: An 11-year study
References (34)
- et al.
Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy
Tubercle
(1971) Consensus Meeting on: causality assessment of drug-induced liver injury
J Hepatol
(1988)- et al.
Toxic hepatitis with isoniazid and rifampicin
- et al.
Isoniazid-Rifampicin-induced hepatitis in hepatitis B carriers
Gastroenterol
(1990) - et al.
Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis
Tubercle Lung Dis
(1994) - et al.
Jaundice associated with rifampicin
Tubercle
(1970) - et al.
Rifampicin hepatitis
Lancet
(1974) The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide
Tubercle
(1978)- et al.
Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis
Am Rev Respir Dis
(1978) - et al.
Hepatic dysfunction in undernourished patients receiving isoniazid and rifampicin
Top Geograph Med
(1990)
Pulmonary tuberculosis with chemotherapy related dysfunction
Kakkaku
(1990)
Hepatotoxicidad del tratamiento de la tuberculosis
Med Clin (Barc)
(1991)
Hepatic complications of antituberculous therapy
Quat J Med
(1975)
Short-course chemotherapy
Chest
(1981)
Six-month isoniazid-rifampicin therapy for tuberculosis
Am Rev Respir Dis
(1984)
USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability
Ann Int Med
(1990)
Toxic affects of isoniazid in tuberculosis chemoprophylaxis
J Am Med Ass
(1979)
Cited by (152)
Biochemical mechanisms of drug toxicity
2021, Atkinson's Principles of Clinical PharmacologyHeavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers
2018, Clinical Gastroenterology and HepatologyUrgent Living-Donor Liver Transplantation in a Patient With Concurrent Active Tuberculosis: A Case Report
2018, Transplantation ProceedingsCitation Excerpt :One study found an overall MTB infection mortality rate of 29% in all solid organ transplantation (SOT) recipients [8], and another study reported a 31% short-term overall, and an 18% MTB infection-specific, mortality rate [7]. For LT patients, 2 issues need to be considered: LT after anti-TB-drug–induced liver failure and TB reactivation after LT. An anti-TB regimen is a leading cause of drug-induced liver disease, which may vary from an asymptomatic presentation to ALF in 0.6% to 2.6% of cases, respectively [10–12]. The range of liver damage can vary significantly, from asymptomatic transaminase elevation in 2% to 28% of cases to ALF in <0.01% of cases [12,13].
Idiosyncratic Adverse Drug Reactions
2018, Comprehensive Toxicology: Third EditionIdiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
2018, Comprehensive Toxicology: Third EditionDrug-Induced Liver Disease
2017, Comprehensive Medicinal Chemistry III
Copyright © 1996 Published by Elsevier Ltd.